Seizert Capital Partners LLC Has $13.94 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Seizert Capital Partners LLC lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 59.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,906 shares of the biotechnology company’s stock after acquiring an additional 14,465 shares during the quarter. Seizert Capital Partners LLC owned approximately 0.09% of United Therapeutics worth $13,942,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Sei Investments Co. boosted its stake in United Therapeutics by 3.2% in the first quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company’s stock worth $8,562,000 after purchasing an additional 1,149 shares in the last quarter. ProShare Advisors LLC grew its holdings in United Therapeutics by 2.1% during the 1st quarter. ProShare Advisors LLC now owns 5,589 shares of the biotechnology company’s stock worth $1,284,000 after acquiring an additional 117 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in United Therapeutics by 2.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 48,197 shares of the biotechnology company’s stock valued at $10,794,000 after acquiring an additional 1,200 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of United Therapeutics by 19.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the last quarter. Finally, Intech Investment Management LLC raised its stake in shares of United Therapeutics by 1,973.9% in the first quarter. Intech Investment Management LLC now owns 19,412 shares of the biotechnology company’s stock worth $4,459,000 after acquiring an additional 18,476 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $363.25 on Friday. The company has a 50 day moving average price of $362.93 and a two-hundred day moving average price of $328.17. The company has a market capitalization of $16.22 billion, a PE ratio of 15.95, a PEG ratio of 1.06 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.38 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research reports. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group boosted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Wells Fargo & Company raised their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. This represents a 74.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher Causey sold 510 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,396 shares of company stock worth $42,175,418 over the last ninety days. 11.90% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.